Pharmacokinetics of azithromycin in serum and sinus fluid after administration of extended-release and immediate-release formulations in patients with acute bacterial sinusitis

International Journal of Antimicrobial Agents

Volumn 31, Issue 6, 2008, Pages 561-566

  Ehnhage, A ^a   Rautiainen, M ^b   Fang, A F ^c   Sanchez, S P ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c PFIZER INC   (United States)

Author keywords

Acute bacterial sinusitis; Azithromycin extended release; Pharmacokinetics; Sinus fluid

Indexed keywords

AZITHROMYCIN;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG RELEASE; DRUG SINUS FLUID LEVEL; DRUG TISSUE LEVEL; EXTENDED RELEASE FORMULATION; FACE PAIN; FATIGUE; FLATULENCE; GASTROINTESTINAL PAIN; HEADACHE; HUMAN; IMMEDIATE RELEASE FORMULATION; LOW DRUG DOSE; MULTICENTER STUDY; NOSE CONGESTION; PARANASAL SINUS; PARANASAL SINUS DISEASE; POST NASAL DRIP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SINUSITIS;

ACUTE DISEASE; ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZITHROMYCIN; BODY FLUIDS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARANASAL SINUSES; SINUSITIS;

EID: 43549122049     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.01.027     Document Type: Article

References (14)

1. Blumer J.L. Evolution of a new drug formulation: the rationale for high-dose, short-course therapy with azithromycin. Int J Antimicrob Agents 26 (2005) 143-147
2. Danesi R., Lucchi M., Pasqualetti G., et al. Single-dose azithromycin microspheres achieves improved lung pharmacokinetics versus azithromycin tablets. Program and Abstracts of the 2006 American Thoracic Society (ATS) International Conference. San Diego, CA (May 2006) Abstract A62
3. Girard D., Finegan S.M., Dunne M.W., and Lame M.E. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 56 (2005) 365-371
4. Murray J.J., Emparanza P., Lesinskas E., Tawadrous M., and Breen J.D. Efficacy and safety of a novel, single-dose azithromycin microsphere formulation versus 10 days of levofloxacin for the treatment of acute bacterial sinusitis in adults. Otolaryngol Head Neck Surg 133 (2005) 194-200
5. Drehobl M.A., De Salvo M.C., Lewis D.E., and Breen J.D. Single-dose azithromycin microspheres vs. clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults. Chest 128 (2005) 2230-2237
6. D'Ignazio J., Camere M.A., Lewis D.E., Jorgensen D., and Breen J.D. Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults. Antimicrob Agents Chemother 49 (2005) 4035-4041
7. Zervos M., Breen J.D., Jorgensen D.M., and Goodrich J.M. Novel, single-dose microsphere formulation of azithromycin versus levofloxacin for the treatment of acute exacerbation of chronic bronchitis. Infect Dis Clin Prac 13 (2005) 115-121
8. Ambrose P.G., Anon, Owen J.S., et al. Use of pharmacodynamic end points in the evaluation of gatifloxacin for the treatment of acute maxillary sinusitis. Clin Infect Dis 38 (2004) 1513-1520
9. Anon, Paglia M., Xiang J., Ambrose P.G., Jones R.N., and Kahn J.B. Serial sinus aspirate samples during high-dose, short-course levofloxacin treatment of acute maxillary sinusitis. Diagn Microbiol Infect Dis 57 (2007) 105-107
10. Rennard S.I., Basset G., Lecossier D., et al. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60 (1986) 532-538
11. Azithromycin [package insert]. New York, NY: Pfizer Inc.; 2006.
12. Foulds G., Shepard R.M., and Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 (1990) 73-82
13. Gladue R.P., Bright G.M., Isaacson R.E., and Newborg M.F. In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 33 (1989) 277-282
14. Karma P., Pukander J., and Penttila M. Azithromycin concentrations in sinus fluid and mucosa after oral administration. Eur J Clin Microbiol Infect Dis 10 (1991) 856-859